Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Z Gerontol Geriatr ; 51(2): 206-212, 2018 Feb.
Article in German | MEDLINE | ID: mdl-27436219

ABSTRACT

OBJECTIVE: The aim of this study was to analyze the possible reasons for acute admission to a department for geriatric psychiatry. The reasons for hospitalization, the psychiatric and somatic comorbidities of the patients over 65 years old with schizophrenia, schizoaffective disorder and delusional disorder were examined to identify patterns and risk profiles. MATERIAL AND METHODS: A retrospective analysis was carried out using paper and electronic patient records of a department of acute care for geriatric psychiatry and psychotherapy. During the assessment period 206 successive patients over 65 years old were included in the study. The patient cohort included 64 patients with schizophrenia according to the international classification of diseases 10 (ICD-10, category F20), 78 patients with persistent delusional disorder (ICD-10, F22) and 64 patients with schizoaffective disorder (ICD-10, F25). RESULTS: The reason for admission for one third of the patients in all three groups was aggressive behavior, whereas delusions and hallucinations were more frequent in the groups of F20 and F22 patients than in patients with schizoaffective disorders (F25). Somatic comorbidities were seen significantly more often in the group of F22 patients than in the other two groups. CONCLUSION: Acute admission was essentially due to acute psychiatric symptoms. Additional somatic comorbidities and psychosocial influencing factors played only a minor role in this study. The patients examined in this study constituted a special group within the acute treatment of inpatient psychiatry because they showed distinctive psychopathological productive symptoms but were relatively healthy from a somatic point of view. Patients with the diagnosis of schizophrenia (F20) or schizoaffective disorder (F25) were significantly different from patients classified into the group of delusional disorders (F22).


Subject(s)
Patient Admission/statistics & numerical data , Psychiatric Department, Hospital/statistics & numerical data , Psychotic Disorders/epidemiology , Schizophrenia, Paranoid/epidemiology , Schizophrenia/epidemiology , Schizophrenic Psychology , Aged , Aged, 80 and over , Aggression/psychology , Austria , Comorbidity , Cross-Sectional Studies , Female , Hallucinations/diagnosis , Hallucinations/epidemiology , Hallucinations/psychology , Humans , Male , Psychotic Disorders/diagnosis , Psychotic Disorders/psychology , Retrospective Studies , Risk Factors , Schizophrenia/diagnosis , Schizophrenia, Paranoid/diagnosis , Schizophrenia, Paranoid/psychology
2.
Z Gerontol Geriatr ; 47(5): 425-38; quiz 439-40, 2014 Jul.
Article in German | MEDLINE | ID: mdl-24609425

ABSTRACT

Delirium, the acute deterioration of cognitive function and attention, is the most frequent mental disorder in elderly. Its correct diagnosis and adequate management are of crucial importance for the patient's health and functional outcome. First of all, one has to be aware of the possibilities of preventing this complex, potentially life-threatening problem, which means recognizing the patient at risk, avoiding environmental stress and causal factors (i.e., anticholinergic medication) in cognitively impaired patients, and timely reaction to prodromal symptoms. Causal therapy (i.e., treatment of the causal condition and/or eliminating the precipitating situation) is imperative. It must be accompanied by nursing and environmental measures and, if necessary, by antipsychotic and/or sedating symptomatic treatment.


Subject(s)
Antipsychotic Agents/administration & dosage , Cognition Disorders/diagnosis , Delirium/diagnosis , Delirium/prevention & control , Geriatric Assessment/methods , Hypnotics and Sedatives/administration & dosage , Aged , Aged, 80 and over , Cognition Disorders/psychology , Cognition Disorders/therapy , Combined Modality Therapy/methods , Delirium/psychology , Female , Germany , Humans , Male , Patient Care Team/organization & administration , Prodromal Symptoms , Symptom Assessment
3.
J Neural Transm (Vienna) ; 118(8): 1255-9, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21461744

ABSTRACT

Memantine is an N-methyl-D: -aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this 'real-life' setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.


Subject(s)
Alzheimer Disease/drug therapy , Alzheimer Disease/psychology , Memantine/therapeutic use , Product Surveillance, Postmarketing/methods , Severity of Illness Index , Aged , Aged, 80 and over , Alzheimer Disease/diagnosis , Female , Humans , Male , Prospective Studies , Treatment Outcome
4.
Neuropsychiatr ; 24(2): 67-87, 2010.
Article in German | MEDLINE | ID: mdl-20605003

ABSTRACT

The Austrian Alzheimer Society developed evidence-based guidelines based on a systematic literature search and criteria-guided assessment with subsequent transparent determination of grades of clinical recommendation. The authors evaluated currently available therapeutic approaches for the most common forms of dementia and focused on diagnosis and pharmacological intervention, taking into consideration the situation in Austria. The purpose of these guidelines is the rational and cost-effective use of diagnostic and therapeutic measures in dementing illnesses. Users are physicians and all other providers of care for patients with dementia in Austria.


Subject(s)
Dementia/diagnosis , Dementia/drug therapy , Evidence-Based Medicine , Nootropic Agents/therapeutic use , Aged , Aged, 80 and over , Amino Acids/adverse effects , Amino Acids/therapeutic use , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Cholinesterase Inhibitors/adverse effects , Cholinesterase Inhibitors/therapeutic use , Cognition Disorders/diagnosis , Cognition Disorders/drug therapy , Cross-Sectional Studies , Dementia/epidemiology , Dementia/etiology , Drug Therapy, Combination , Female , Ginkgo biloba , Humans , Incidence , Life Style , Long-Term Care , Male , Medication Adherence , Memantine/adverse effects , Memantine/therapeutic use , Middle Aged , Plant Extracts/adverse effects , Plant Extracts/therapeutic use , Population Dynamics , Psychotropic Drugs/adverse effects , Psychotropic Drugs/therapeutic use , Randomized Controlled Trials as Topic
5.
Pharmacopsychiatry ; 40(3): 129-31, 2007 May.
Article in English | MEDLINE | ID: mdl-17541890

ABSTRACT

Elderly patients are at a higher risk for inappropriate antidiuretic hormone secretion when treated with antidepressants. In response to severe depressive symptoms, we initiated treatment with citalopram of an 81-year-old female patient with slightly reduced sodium and chloride levels. The sodium and chloride levels decreased continuously during treatment with citalopram; six days after the citalopram was discontinued, sodium and chloride levels returned to normal. We then switched treatment to mirtazapine. Close monitoring revealed that the patient's sodium and chloride levels never decreased and the patient did not relapse for more than two months. This case study indicates that treatment with citalopram may worsen preexisting hyponatremia. Mirtazapine appears to be safe for use in high-risk, elderly patients.


Subject(s)
Antidepressive Agents, Tricyclic/therapeutic use , Depressive Disorder, Major/drug therapy , Inappropriate ADH Syndrome/chemically induced , Mianserin/analogs & derivatives , Aged, 80 and over , Antidepressive Agents, Second-Generation/adverse effects , Citalopram/adverse effects , Female , Humans , Inappropriate ADH Syndrome/physiopathology , Male , Mianserin/therapeutic use , Mirtazapine
SELECTION OF CITATIONS
SEARCH DETAIL
...